Working… Menu

Early-Phase Study to Assess Inhibitor Ribociclib in Patients With Recurrent Glioblastoma or Anaplastic Glioma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02345824
Recruitment Status : Unknown
Verified June 2018 by Camilo E. Fadul, MD, University of Virginia.
Recruitment status was:  Active, not recruiting
First Posted : January 26, 2015
Last Update Posted : June 7, 2018
Novartis Pharmaceuticals
Information provided by (Responsible Party):
Camilo E. Fadul, MD, University of Virginia

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : September 2019
Estimated Study Completion Date : January 2020